Filing Details
- Accession Number:
- 0001127602-10-008867
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-03-16 13:00:00
- Reporting Period:
- 2010-03-15
- Filing Date:
- 2010-03-16
- Accepted Time:
- 2010-03-16 19:05:55
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 882796 | Biocryst Pharmaceuticals Inc | BCRX | Biological Products, (No Disgnostic Substances) (2836) | 621413174 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1033507 | P Zola Horovitz | 2190 Parkway Lake Drive Birmingham AL 35244- | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2010-03-15 | 10,000 | $2.60 | 13,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2010-03-15 | 10,000 | $7.22 | 3,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2010-03-15 | 10,000 | $0.00 | 10,000 | $2.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2004-05-14 | 2013-05-14 | No | 4 | M | Direct |
Footnotes
- Transacted under a 10b5-1 plan that was adopted on 11/24/2009.
- The price in column 4 is a weighted average price. The prices actually ranged from $7.11 to $7.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.
Billionaire Hedge Funds
